Clinical Trials Directory

Trials / Completed

CompletedNCT01069302

Clopidogrel High Dose Evaluation for the Patient With Coronary Artery Disease in Japan

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
106 (actual)
Sponsor
Takeshi Morimoto · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the effect of high dose clopidogrel as the antiplatelet therapy on inhibition of platelet aggregation in Japanese patients scheduled for percutaneous coronary intervention due to ischemic heart disease.

Detailed description

Dual antiplatelet therapy of aspirin and thienopyridine is used to prevent stent thrombosis after percutaneous coronary intervention (PCI). Clopidogrel is the most popular thienopyridine. Following the 300mg clopidogrel loading dose (LD) at first day, patients take 75mg maintenance dose (MD) to inhibit platelet aggregation after coronary stent implantation. 600mg high LD inhibit platelet aggregation more rapidly and strongly than standard LD and prevent thrombotic event around the PCI. Similarly high MD inhibit platelet aggregation more strongly. Interindividual variability of clopidogrel anti-platelet effect has been reported. In Japanese, there are many non or hyporesponders to clopidogrel compared to the Western population. The purpose of this study is to evaluate the effect of high dose clopidogrel as the antiplatelet therapy on inhibition of platelet aggregation in Japanese patients scheduled for PCI due to ischemic heart disease.

Conditions

Interventions

TypeNameDescription
DRUGClopidogrelClopidogrel loading 600mg and maintenance 150mg for 7days
DRUGClopidogrelClopidogrel loading 600mg and maintenance 75mg for 7days
DRUGClopidogrelClopidogrel loading 300mg and maintenance 150mg for 7days
DRUGClopidogrelClopidogrel loading 300mg and maintenance 75mg for 7days

Timeline

Start date
2010-02-01
Primary completion
2011-11-01
Completion
2011-12-01
First posted
2010-02-17
Last updated
2016-01-11

Locations

1 site across 1 country: Japan

Source: ClinicalTrials.gov record NCT01069302. Inclusion in this directory is not an endorsement.